Deletion or neutralization of ESM1 significantly inhibited tumor growth and overcame bevacizumab resistance in triple negative breast cancer, thus confirming that ESM1 was a key molecule mediating bevacizumab resistance. Here, ESM1 is linked to neoplasm.